IR Pellets Manufacturer & Supplier

Innovative IR Products For Advanced Therapeutics

Empowering better health with scientifically formulated Immediate Release (IR) pellets and advanced pharmaceutical solutions. Credo Life Sciences is a trusted pharmaceutical solutions provider, specializing in the development and manufacturing of Immediate Release (IR) products and pellet-based formulations. With WHO-GMP certified facilities, state-of-the-art R&D infrastructure, and stringent quality controls, we ensure global-standard pharmaceutical products that empower healthcare companies and improve patient outcomes.

About IR Products

Immediate Release (IR) products are formulated to ensure rapid absorption, enhanced bioavailability, and effective therapeutic action. Credo’s IR products are designed to deliver high-quality formulations that comply with international standards, making us a trusted partner for pharmaceutical companies, distributors, and contract manufacturers.

One of the key advantages of IR pellets is their ability to provide consistent and predictable performance. By controlling particle size, coating, and formulation techniques, these pellets maintain uniform drug release profiles, minimizing variability between doses. This helps improve patient safety, compliance, and overall treatment outcomes.

IR pellets also offer versatility in dosage forms, as they can be incorporated into tablets, capsules, or sachets. This flexibility allows pharmaceutical companies to design patient-friendly medications that suit different needs while maintaining efficacy. As a result, IR pellet technology plays a vital role in modern drug delivery systems, supporting innovation in healthcare.

Key Features

High Stability

Formulated to maintain integrity and effectiveness during storage.

Global Quality Standards

Manufactured under strict GMP and international compliance norms.

Consistent Performance

Uniform drug release ensuring reliable bioavailability

Customizable Formulations

Tailored solutions to meet diverse therapeutic needs.

Advanced Drug Delivery

Engineered with precision technology for improved therapeutic outcomes

Enhanced Bioavailability

Optimized formulation ensures better absorption and therapeutic efficiency.

IR Product Portfolio

Product Name	Percentage Available	Therapeutic Usage
Atorvastatin	7.5%, 15%	Lipid-Lowering Agent
Clopidogrel	40%	Antiplatelet Agent
Dutasteride	0.5%	Benign Prostatic Hyperplasia
Fenofibrate	66.23%	Cholesterol Control
Itraconazole	20%, 22%, 30%, 32.5%, 40%	Antifungal Treatment
Mebeverine HCl	40%	IBS & Gastrointestinal Care
Orlistat	50%	Weight Management
Rosuvastatin	7.5%, 15%, 30%	Lipid-Lowering Agent